| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/14651858.CD005162.PUB3 |
| P8608 | Fatcat ID | release_wgihwadnqnd3bhoip7b3qf2gma |
| P3181 | OpenCitations bibliographic resource ID | 4437949 |
| P698 | PubMed publication ID | 22972083 |
| P50 | author | Lise Lotte Gluud | Q28037191 |
| Aleksander Krag | Q56849497 | ||
| P2093 | author name string | Erik Christensen | |
| Kurt Christensen | |||
| P2860 | cites work | Terlipressin for hepatorenal syndrome | Q24243962 |
| Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis | Q24289436 | ||
| Sequential methods for random-effects meta-analysis | Q24289522 | ||
| Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study | Q24653790 | ||
| The role of vasopressin in vasodilatory septic shock | Q33362358 | ||
| Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem | Q33870263 | ||
| Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study | Q33966802 | ||
| Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. | Q34011626 | ||
| Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites | Q34062056 | ||
| Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club | Q34062215 | ||
| Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome. | Q34600578 | ||
| Review article: pathogenesis and pathophysiology of hepatorenal syndrome--is there scope for prevention? | Q35873829 | ||
| Bias in clinical intervention research. | Q36380552 | ||
| A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome | Q37061659 | ||
| Terlipressin in hepatorenal syndrome: a systematic review and meta-analysis | Q37438171 | ||
| Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. | Q37626627 | ||
| Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials | Q37674956 | ||
| Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial | Q44287768 | ||
| Worsening of cerebral hyperemia by the administration of terlipressin in acute liver failure with severe encephalopathy. | Q44759297 | ||
| Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study | Q45003218 | ||
| An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response | Q46537222 | ||
| Circulatory function and hepatorenal syndrome in cirrhosis. | Q46565582 | ||
| Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. | Q46948629 | ||
| Hepatorenal syndrome | Q56683659 | ||
| Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome | Q56925565 | ||
| Controlled trial of terlipressin ('Glypressin') versus vasopressin in the early treatment of oesophageal varices | Q72528478 | ||
| Circadian Rhythm of Arginine Vasopressin in Hepatorenal Syndrome | Q74132999 | ||
| P921 | main subject | hepatorenal syndrome | Q247131 |
| P577 | publication date | 2012-09-12 | |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Terlipressin for hepatorenal syndrome |
| Q43787030 | 6 years of the International Union of Societies of Immunology. Presidential report (Brighton 1974) |
| Q36515680 | AISF-SIMTI position paper: the appropriate use of albumin in patients with liver cirrhosis |
| Q26775643 | Acute Kidney Injury in Patients with Cirrhosis |
| Q38243669 | Acute kidney injury and hepatorenal syndrome in cirrhosis. |
| Q34228579 | Acute kidney injury: quoi de neuf? |
| Q37429032 | Clinical course and prognostic factors of hepatorenal syndrome: A retrospective single-center cohort study |
| Q37370312 | Clinical use of albumin |
| Q26795734 | Creatinine Change on Vasoconstrictors as Mortality Surrogate in Hepatorenal Syndrome: Systematic Review & Meta-Analysis |
| Q41059672 | Current position of vasoconstrictor and albumin infusion for type 1 hepatorenal syndrome |
| Q38168180 | Drug therapies in liver disease. |
| Q94475967 | Effect of terlipressin on renal function in cirrhotic patients with acute upper gastrointestinal bleeding |
| Q38849427 | Evidence-based clinical practice guidelines for liver cirrhosis 2015. |
| Q91877647 | Hepatorenal Syndrome |
| Q91828497 | Hepatorenal Syndrome Type 1: Current Challenges And Future Prospects |
| Q36876331 | Hepatorenal syndrome:Response to terlipressin and albumin and its determinants |
| Q34475601 | Management of cirrhotic ascites |
| Q38463841 | Management of hepatorenal syndrome |
| Q47807120 | New Developments in Hepatorenal Syndrome |
| Q37312786 | No difference in mortality between terlipressin and somatostatin treatments in cirrhotic patients with esophageal variceal bleeding and renal functional impairment |
| Q91625935 | Novel use of Cytosorb™ haemadsorption to provide biochemical control in liver impairment |
| Q91841947 | Pharmacological treatment of hepatorenal syndrome: a network meta-analysis |
| Q38565163 | Prognosis of Acute Kidney Injury and Hepatorenal Syndrome in Patients with Cirrhosis: A Prospective Cohort Study |
| Q50084092 | Prognosis of Patients with Cirrhosis and AKI Who Initiate RRT. |
| Q91272486 | Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis |
| Q57824694 | Renal Failure in Patients with Liver Cirrhosis: Novel Classifications, Biomarkers, Treatment |
| Q35559713 | Renal dysfunction in cirrhosis |
| Q33558945 | Systematic review of pathophysiological changes following hepatic resection |
| Q64236970 | Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2 |
| Q55112410 | Terlipressin in the treatment of hepatorenal syndrome: A systematic review and meta-analysis. |
| Q35244409 | Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis |
| Q24188350 | Terlipressin versus other vasoactive drugs for hepatorenal syndrome |
| Q47737114 | Terlipressin versus other vasoactive drugs for hepatorenal syndrome. |
| Q38962412 | Therapeutic alternatives for the treatment of type 1 hepatorenal syndrome: A Delphi technique-based consensus |
| Q24198269 | Transjugular intrahepatic portosystemic shunts for hepatorenal syndrome |
| Q39029019 | Treatment to improve acute kidney injury in cirrhosis |
| Q47963528 | Vasoactive Agents for Hepatorenal Syndrome: A Mixed Treatment Comparison Network Meta-Analysis and Trial Sequential Analysis of Randomized Clinical Trials. |
Search more.